Jane Street
INM icon

Jane Street’s InMed Pharmaceuticals INM Stock Holding History

Jane Street’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.8K Buy
+43,078
New +$47.6K ﹤0.01% 10806
2026
Q1 		– Sell
-11,978
Closed -$12.7K – 12240
2025
Q4 		$12.7K Buy
+11,978
New +$19.9K ﹤0.01% 10803

Other funds holding INM

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UFM
Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street's INM Position: Q2 2026 in Review

Jane Street opened a new position in InMed Pharmaceuticals (INM) in Q2 2026: 43,078 shares worth $66.8K. The stake represents ﹤0.01% of the portfolio and ranks #10806 among its holdings. This is a return to the name: Jane Street previously reported a position in INM as recently as Q4 2025.

Jane Street first reported a position in INM in Q4 2025 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

  • Jane Street held 43,078 shares of InMed Pharmaceuticals worth $66.8K as of Q2 2026.
  • InMed Pharmaceuticals was a new Jane Street position in Q2 2026.
  • InMed Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10806 holding.
  • Jane Street first reported a position in InMed Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.